Trial of Pimavanserin in Dementia-Related Psychosis | Zendy

Pierre N. Tariot | Zendy; Jeffrey L. Cummings | Zendy; María Soto-Martín | Zendy; Clive Ballard | Zendy; Deniz ErtenLyons | Zendy; David L. Sultzer | Zendy; Davangere P. Devanand | Zendy; Daniel Weintraub | Zendy; Bradley McEvoy | Zendy; James M. Youakim | Zendy; Srdjan Stankovic | Zendy; Erin P. Foff | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trial of Pimavanserin in Dementia-Related Psychosis

Author(s) -

Pierre N. Tariot,

Jeffrey L. Cummings,

María Soto-Martín,

Clive Ballard,

Deniz ErtenLyons,

David L. Sultzer,

Davangere P. Devanand,

Daniel Weintraub,

Bradley McEvoy,

James M. Youakim,

Srdjan Stankovic,

Erin P. Foff

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2034634

Subject(s) - dementia , psychosis , dementia with lewy bodies , antipsychotic , discontinuation , clinical global impression , vascular dementia , psychology , psychiatry , placebo , medicine , disease , schizophrenia (object oriented programming) , pathology , alternative medicine

Patients with dementia due to neurodegenerative disease can have dementia-related psychosis. The effects of the oral 5-HT 2A inverse agonist and antagonist pimavanserin on psychosis related to various causes of dementia are not clear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research